---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003482"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:59:45.990863+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Q1 2022 net loss $7.8M ($0.23/share); cash $34.7M; clinical milestones on track

## Summary
- Net loss $7.8M vs $3.8M YoY; per share loss $0.23 vs $0.16; non-cash expenses $813K.
- Cash balance $34.7M at March 31, 2022; projected FY 2022 cash burn $16.8M.
- R&D expenses $5.3M (+70% YoY) and G&A $2.1M (+253% YoY) due to increased activity.
- Clinical data readouts for agenT-797 in solid tumors and ARDS on track for 2H 2022.
- GMP manufacturing launch anticipated in 1H 2022 with target 10,000 doses/yr.

## SEC filing metadata
- accession: 0001171843-22-003482
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184322003482/0001171843-22-003482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184322003482/f8k_051022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003482
- JSON: https://secwatch.observer/filing/0001171843-22-003482.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.